"Mid Atlantic Retina is an internationally recognized, pre-eminent retina practice in Pennsylvania, New Jersey and Delaware delivering state-of-the-art, comprehensive patient care for over 40 years. Our retina specialists are world-renowned and board-certified physicians with over 400 years of combined expertise. They are recognized as leaders in vitreoretinal diseases by ophthalmology and medical societies. We are dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of restoring and maintaining sight to improve the quality of life for our patients. See a Wills Eye Doctor in Philadelphia today."

During the past decade, Mid Atlantic Retina - Wills Eye Hospital conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 11 clinical trials were completed, i.e. on average, 78.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mid Atlantic Retina - Wills Eye Hospital" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Wills Eye" with 2 trials sponsored, "Aerie Pharmaceuticals" with 1 trials sponsored and "LumiThera, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mid Atlantic Retina - Wills Eye Hospital" #1 collaborator was "Mid Atlantic Retina" with 1 trials as a collaborator, "Physician Recommended Nutriceuticals" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Mid Atlantic Retina - Wills Eye Hospital" are "Macular Degeneration" (3 trials), "Neovascular Age-related Macular Degeneration" (3 trials), "Diabetic Macular Edema" (2 trials), "Geographic Atrophy" (2 trials) and "Neovascular Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Mid Atlantic Retina - Wills Eye Hospital" in a lesser frequency.

Most popular intervention types in "Mid Atlantic Retina - Wills Eye Hospital" are "Drug" (15 trials), "Procedure" (4 trials), "Device" (2 trials), "Other" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Faricimab" (5 trials), "Sham Procedure" (5 trials), "Aflibercept" (4 trials), "Lampalizumab" (2 trials) and "25mg Eplerenone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mid Atlantic Retina - Wills Eye Hospital" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Mid Atlantic Retina - Wills Eye Hospital". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Mid Atlantic Retina - Wills Eye Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Mid Atlantic Retina - Wills Eye Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".